Generalized Anxiety Disorder Market Report and Forecast 2024-2032

Generalized Anxiety Disorder Market Report and Forecast 2024-2032


Generalized Anxiety Disorder Market Report and Forecast 2024-2032

Generalized Anxiety Disorder Market Outlook

The generalized anxiety disorder market size was valued at USD 1717.5 million in 2023, driven by growing recognition of generalized anxiety disorder as a serious mental health condition. The market size is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032 to achieve a value of USD 2751.1 million by 2032.

Generalized Anxiety Disorder: Introduction

Generalized anxiety disorder (GAD) is a chronic mental health condition characterized by persistent and excessive worry about various aspects of daily life, often without a specific cause. Individuals with GAD find it difficult to control their anxiety, leading to symptoms such as restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbances. GAD can significantly impair daily functioning and is often accompanied by other mood or anxiety disorders, necessitating professional evaluation and treatment.

Key Trends in the Generalized Anxiety Disorder Market

Globally, there's a growing recognition of GAD as a serious mental health condition. Enhanced awareness among the public and healthcare professionals is leading to more frequent diagnosis and a higher reported prevalence.

There's a trend towards personalized treatment plans, combining pharmacotherapy (like SSRIs and SNRIs) with psychotherapy (particularly Cognitive Behavioral Therapy). Research into new medication classes and therapy forms is ongoing, aiming to improve outcomes and reduce side effects.

The adoption of digital tools, including mobile apps for anxiety management and teletherapy services, is on the rise. These tools offer accessible and flexible treatment options, particularly important in regions with limited mental health resources.

There's a growing emphasis on holistic and integrated care approaches, combining mental health services with primary care to ensure comprehensive management of GAD, especially given its frequent comorbidity with other health conditions.

Various regions are witnessing increased governmental and non-governmental investment in mental health services, aiming to improve access to care and support mental health research.

Efforts to reduce stigma around mental health and promote mental wellbeing are contributing to a more open environment for discussing and treating GAD.

Generalized Anxiety Disorder Market Segmentation

Market Breakup by Therapeutic Type
  • Antidepressant
  • Buspirone
  • Benzodiazepines
Market Breakup by Therapy Type
  • Interpersonal Therapy
  • Behavior Therapy
  • Cognitive Behavioral Therapy
  • Mindfulness Based Cognitive Therapy
Market Breakup by Diagnosis
  • Deep Brain Stimulation
  • Electroconvulsive Therapy
  • Transcranial Magnetic
  • Stimulation Vagus Nerve
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Generalized Anxiety Disorder Market Overview

North America market is well-established, particularly in the U.S. and Canada, with a high awareness of mental health issues and a wide range of treatment options available, including medication, psychotherapy, and integrated care models. There's a growing focus on personalized medicine and digital health solutions like teletherapy.

Europe shows a strong emphasis on healthcare provision and mental health services, with countries like the UK, Germany, and France leading in terms of GAD treatment and research. The region is known for its comprehensive healthcare systems that include mental health services and a growing acceptance of mental health issues.

Japan market is growing, driven by increasing awareness of mental health conditions and improvements in healthcare infrastructure. The region is investing in mental health services, though cultural stigmas around mental health can impact the willingness to seek treatment.

Generalized Anxiety Disorder Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Eli Lilly and Company
  • GlaxoSmithKline Pharmaceuticals Limited
  • Pfizer, Inc.
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Actavis Pharmaceutical Company
  • F. Hoffmann-La Roche
  • Sumitomo Dainippon Pharma
  • MindMed
  • VistaGen Therapeutics, Inc
  • Mitsubishi Chemical Group Corporation
  • Sanofi
  • Mitsubishi Chemical Group Corporation
  • Forest Laboratories, Inc
  • H. Lundbeck A/S
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Generalized Anxiety Disorder Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Generalized Anxiety Disorder Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3.1 Germany Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3.2 France Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3.3 Italy Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3.4 Spain Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
5.4 Japan Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
6 Generalized Anxiety Disorder Market Overview – 7MM
6.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
6.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
7 Generalized Anxiety Disorder Market Landscape – 7MM
7.1 Generalized Anxiety Disorder: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Generalized Anxiety Disorder Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Treatment Type
8 Generalized Anxiety Disorder Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Generalized Anxiety Disorder Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Generalized Anxiety Disorder Market Segmentation – 7MM
11.1 Generalized Anxiety Disorder Market by Therapeutic Type
11.1.1 Market Overview
11.1.2 Antidepressant
11.1.3 Buspirone
11.1.4 Benzodiazepines
11.2 Generalized Anxiety Disorder Market by Therapy Type
11.2.1 Market Overview
11.2.2 Interpersonal Therapy
11.2.3 Behavior Therapy
11.2.4 Cognitive Behavioral Therapy
11.2.5 Mindfulness Based Cognitive Therapy
11.3 Generalized Anxiety Disorder Market by Diagnosis
11.3.1 Market Overview
11.3.2 Deep Brain Stimulation
11.3.3 Electroconvulsive Therapy
11.3.4 Transcranial Magnetic
11.3.5 Stimulation Vagus Nerve
11.4 Generalized Anxiety Disorder Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Generalized Anxiety Disorder Market
12.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
12.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
12.3 Generalized Anxiety Disorder Market by Disease Type
12.4 Generalized Anxiety Disorder Market by Treatment Type
13 EU-4 and United Kingdom Generalized Anxiety Disorder Market
13.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
13.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
13.3 Germany Generalized Anxiety Disorder Market Overview
13.3.1 Generalized Anxiety Disorder Market by Disease Type
13.3.2 Generalized Anxiety Disorder Market by Treatment Type
13.4 France Generalized Anxiety Disorder Market Overview
13.4.1 Generalized Anxiety Disorder Market by Disease Type
13.4.2 Generalized Anxiety Disorder Market by Treatment Type
13.5 Italy Generalized Anxiety Disorder Market Overview
13.5.1 Generalized Anxiety Disorder Market by Disease Type
13.5.2 Generalized Anxiety Disorder Market by Treatment Type
13.6 Spain Generalized Anxiety Disorder Market Overview
13.6.1 Generalized Anxiety Disorder Market by Disease Type
13.6.2 Generalized Anxiety Disorder Market by Treatment Type
13.7 United Kingdom Generalized Anxiety Disorder Market Overview
13.7.1 Generalized Anxiety Disorder Market by Disease Type
13.7.2 Generalized Anxiety Disorder Market by Treatment Type
14 Japan Generalized Anxiety Disorder Market
14.1 Generalized Anxiety Disorder Market Historical Value (2017-2023)
14.2 Generalized Anxiety Disorder Market Forecast Value (2024-2032)
14.2.1 Generalized Anxiety Disorder Market by Disease Type
14.2.2 Generalized Anxiety Disorder Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Eli Lilly and Company
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 GlaxoSmithKline Pharmaceuticals Limited
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Pfizer, Inc.
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Abbott Laboratories
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Bristol-Myers Squibb
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Actavis Pharmaceutical Company
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 F. Hoffmann-La Roche
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Sumitomo Dainippon Pharma
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 MindMed
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 VistaGen Therapeutics, Inc
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Mitsubishi Chemical Group Corporation
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Sanofi
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Mitsubishi Chemical Group Corporation
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Forest Laboratories, Inc
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 H. Lundbeck A/S
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Generalized Anxiety Disorder Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings